3.Clinical characteristics and evolution of paroxysmal nocturnal hemoglobinuria clones in patients with acquired aplastic anemia.
Jing ZHANG ; Xingxin LI ; Jun SHI ; Meili GE ; Yingqi SHAO ; Jinbo HUANG ; Zhendong HUANG ; Neng NIE ; Yizhou ZHENG
Chinese Journal of Hematology 2016;37(2):124-129
OBJECTIVETo explore the clinical characteristics, and the effect of paroxysmal nocturnal hemoglobinuria (PNH) clone size and its evolution on response and survival in aplastic anemia (AA) patients.
METHODSThe clinical data of 90 AA cases with PNH clones from 316 AA patients between January 2011 and September 2014 were retrospectively reviewed, their clinical characteristics were analyzed, and the influence of PNH clone evolution and size on response and survival were explored.
RESULTS① Of 316 patients, 90 cases (28.5%) with PNH clones. Of 83 cases with long-term follow-up data available, the complete (CR) and partial response (PR) rates were 43.4% and 33.7% respectively, with the overall responsive rate of 77.1%. The 3-year and 5-year overall survival (OS)rates were 79.4% and 76.1% respectively. ② After immunosuppressive therapy (IST), the PNH clone changed from negative to positive in 24 cases, persistently positive PNH clones were observed in 22 cases, disappeared in 10 cases. There were no significant differences in terms of overall responsive rates, survival rates, absolute reticulocyte value, TBIL, IBIL and LDH among the three groups (P >0.05). Ten cases became AA-PNH after a median time of 15.6 months, no significant differences were found in overall responsive and survival rates between the 10 cases and the other 46 cases who were monitored for PNH clones (P values were 0.896, 0.688, respectively). ③ According to univariate analysis, age≥55, infection, VSAA, ANC <0.5 × 10(9)/L and absolute reticulocyte value <0.012 × 10(12)/L had significant influence on survival (P values were 0.026, 0.000, 0.001, 0.000 and 0.010, respectively). Cox regression model analysis identified that age, infection and ANC were independent prognostic factors affecting survival (P values were 0.050, 0.012 and 0.050, respectively). The PNH clone size had no significant influence on response and survival based on univariate and Cox analyses.
CONCLUSIONThe PNH clone size and its evolution had no significant influence on response and survival.
Anemia, Aplastic ; complications ; pathology ; Clone Cells ; Hemoglobinuria, Paroxysmal ; complications ; pathology ; Humans ; Immunosuppression ; Reticulocytes ; Retrospective Studies
4.Moyamoya Syndrome Caused by Paroxysmal Nocturnal Hemoglobinuria.
Zhi-Juan CHENG ; Yao-Yao SHEN ; Ishak Mohamed WARSAME ; Ting-Min DAI ; Jiang-Long TU
Chinese Medical Journal 2018;131(23):2874-2876
Adult
;
Hemoglobinuria, Paroxysmal
;
complications
;
pathology
;
Humans
;
Male
;
Moyamoya Disease
;
diagnosis
;
etiology
;
pathology
;
Young Adult
5.The clinical characteristics of 7 paroxysmal nocturnal hemoglobinuria patients initiated with refractory iron-deficiency anaemia.
Ying-xin SUN ; Ming-qing ZHU ; Guang-sheng HE
Chinese Journal of Hematology 2013;34(1):69-70
Adolescent
;
Adult
;
Anemia, Iron-Deficiency
;
diagnosis
;
etiology
;
Child
;
Female
;
Hemoglobinuria, Paroxysmal
;
complications
;
diagnosis
;
Humans
;
Male
;
Middle Aged
;
Young Adult
6.The clinical significance of evolution of paroxysmal nocturnal haemoglobinuria clones in aplastic anemia patients.
Ying-Mei LI ; Xing-Xin LI ; Mei-Li GE ; Jun SHI ; Ying-Qi SHAO ; Lin-Sheng QIAN ; Yi-Zhou ZHENG
Chinese Journal of Hematology 2012;33(2):117-122
OBJECTIVETo explore the clinical significance of evolution of paroxysmal nocturnal hemoglobinuria (PNH) clones in aplastic anemia (AA) patients.
METHODSThe positive rate of PNH clones in 678 AA cases at first diagnosis from January 2002 to December 2009 were analyzed, and to compare the response rate and overall survival (OS) between AA patients with or without PNH clones. All patients were sequentially followed-up to assess the incidence rate and risk factors for AA evolving to overt PNH.
RESULTS(1) Of 119/678 (17.6%) AA patients at initial diagnosis presented with PNH clones,the positive rates of PNH clones among non-severe AA (NSAA), severe AA (SAA) and very severe AA (VSAA) were 16.7% (37/ 222), 17.3% (45/260) and 18.9% (37/196), respectively. There was no statistical difference among the three groups. (Chi2 = 0.369; P = 0.832); (2) 678 newly diagnosed AA cases were divided into 5 subgroups according to PNH clones, severity of disease and treatment regimens. There was no statistical difference among the five subgroups regarding 6m-response rate (RR) and OS. (3) Serial follow-up revealed that persistent PNH negative clones were found in 516 (76.1%) cases, and evolved to PNH positive clones after therapy in 43 (6.3%) cases. Persistent PNH positive clones were found in 72 (10.6%) cases, and disappeared the clones after treatment in 47 (6.9%) cases. There was no statistical difference among the four subgroups in terms of the 6m RR (Chi2 = 2.489,P = 0.426) and OS (P = 0.477); (4) 17 out of 678 AA cases (2.5%) evolved to overt PNH and the estimated incidence of evolution to overt PNH was (3.7 +/- 0.9)% at 10 years. The incidences of AA patients with or without PNH clones at initial diagnosis evolved to overt PNH were 3.4% and 2.3%, respectively. There was no statistical difference between the two groups, (Chi2 = 0.111; P = 0.739); and so was found in OS by Kaplan-Meier analysis (P = 0.868). Cox regression model analysis showed that none of the severity of AA, with or without PNH clone at initial diagnosis, treatment regimen and 6m RR was the risk factor for evolution to overt PNH.
CONCLUSIONThere is no difference between AA patients presented with or without PNH clones at initial diagnosis regarding the RR and prognosis. The appearance of PNH clones in AA is not identified as a risk factor for developing into overt PNH.
Adolescent ; Adult ; Aged ; Anemia, Aplastic ; complications ; pathology ; Child ; Child, Preschool ; Clone Cells ; Female ; Hemoglobinuria, Paroxysmal ; etiology ; pathology ; Humans ; Incidence ; Male ; Middle Aged ; Risk Factors ; Young Adult
7.Predictive Factors of Mortality in Population of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Results from a Korean PNH Registry.
Jun Ho JANG ; Jin Seok KIM ; Sung Soo YOON ; Je Hwan LEE ; Yeo Kyeoung KIM ; Deog Yeon JO ; Jooseop CHUNG ; Sang Kyun SOHN ; Jong Wook LEE
Journal of Korean Medical Science 2016;31(2):214-221
Paroxysmal nocturnal hemoglobinuria (PNH) is a progressive, systemic, life-threatening disease, characterized by chronic uncontrolled complement activation. A retrospective analysis of 301 Korean PNH patients who had not received eculizumab was performed to systematically identify the clinical symptoms and signs predictive of mortality. PNH patients with hemolysis (lactate dehydrogenase [LDH] > or = 1.5 x the upper limit of normal [ULN]) have a 4.8-fold higher mortality rate compared with the age- and sex-matched general population (P < 0.001). In contrast, patients with LDH < 1.5 x ULN have a similar mortality rate as the general population (P = 0.824). Thromboembolism (TE) (odds ratio [OR] 7.11; 95% confidence interval [CI] (3.052-16.562), renal impairment (OR, 2.953; 95% CI, 1.116-7.818) and PNH-cytopenia (OR, 2.547; 95% CI, 1.159-5.597) are independent risk factors for mortality, with mortality rates 14-fold (P < 0.001), 8-fold (P < 0.001), and 6.2-fold (P < 0.001) greater than that of the age- and sex-matched general population, respectively. The combination of hemolysis and 1 or more of the clinical symptoms such as abdominal pain, chest pain, or dyspnea, resulted in a much greater increased mortality rate when compared with patients with just the individual symptom alone or just hemolysis. Early identification of risk factors related to mortality is crucial for the management of PNH. This trial was registered at www.clinicaltrials.gov as NCT01224483.
Adolescent
;
Adult
;
Aged
;
Aged, 80 and over
;
Antibodies, Monoclonal/therapeutic use
;
Antibodies, Monoclonal, Humanized/therapeutic use
;
Area Under Curve
;
Child
;
Dyspnea/etiology
;
Female
;
Hemoglobinuria, Paroxysmal/*diagnosis/drug therapy/mortality
;
Hemolysis
;
Humans
;
Kaplan-Meier Estimate
;
Kidney Diseases/complications/diagnosis
;
L-Lactate Dehydrogenase/metabolism
;
Male
;
Middle Aged
;
Odds Ratio
;
ROC Curve
;
Registries
;
Republic of Korea
;
Retrospective Studies
;
Risk Factors
;
Thromboembolism/complications/diagnosis
;
Young Adult